Key result
DCBs reduce MACE by ~17% vs DES, alongside lower mortality and TLR.
Why the study?
In small vessel coronary artery disease, drug-eluting stents have resulted in increased restenosis rates and adverse events, making drug-coated balloons an attractive alternative without permanent implants.
Do paclitaxel- or sirolimus-coated drug-coated balloons reduce major adverse cardiovascular events compared to drug-eluting stents in patients with de novo small-vessel coronary artery disease?
Comparison
Paclitaxel- or sirolimus-coated DCBs vs any generation DES
Design
Systematic review and meta-analysis of RCTs
Authors
Loading...
Supports DCB preference over DES in small-vessel CAD; strengthens RCT meta-analysis evidence for event reduction.
Do paclitaxel- or sirolimus-coated drug-coated balloons reduce major adverse cardiovascular events compared to drug-eluting stents in patients with de novo small-vessel coronary artery disease?
In patients with de novo small-vessel coronary artery disease, drug-coated balloons are associated with significantly reduced incidences of MACE, TLR, restenosis, MI, and mortality compared to drug-eluting stents.
Khan et al. (2025) studied this question. Drug-coated balloons reduced major adverse cardiovascular events by 17%, target lesion revascularization by 32%, and all-cause mortality by 21% compared to drug-eluting stents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: